TKTL1 as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma and Its Correlation with FDG-PET-CT | Zendy

Kaisa Ahopelto | Zendy; Kapo Saukkonen | Zendy; Jaana Hagström | Zendy; Saila Kauhanen | Zendy; Hanna Seppänen | Zendy; Camilla Böckelman | Zendy; Caj Haglund | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

TKTL1 as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma and Its Correlation with FDG-PET-CT

Author(s) -

Kaisa Ahopelto,

Kapo Saukkonen,

Jaana Hagström,

Saila Kauhanen,

Hanna Seppänen,

Camilla Böckelman,

Caj Haglund

Publication year - 2020

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000510862

Subject(s) - medicine , immunohistochemistry , pancreatic cancer , adenocarcinoma , stage (stratigraphy) , cancer , pancreatic ductal adenocarcinoma , oncology , biology , paleontology

Glucose metabolism in cancer cells differs from noncancerous cells. The expression of transketolase-like protein 1 (TKTL1), a key enzyme in the glucose metabolism of cancer cells, predicts poor prognosis in several cancer types. We studied TKTL1 as a prognostic tool and whether TKTL1 expression correlates with 18F-FDG-PET-CT among patients with pancreatic ductal adenocarcinoma (PDAC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research